Skip to main content
All lobbying filings

Travere Therapeutics

Travere Therapeutics filed a Q1 report for Travere Therapeutics on April 20, 2026.

Lobbying for Travere Therapeutics · Biopharmaceuticals

As filed: TRAVERE THERAPEUTICS for TRAVERE THERAPEUTICS.

All filings by Travere Therapeutics · Everything Travere Therapeutics has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2026
Jan 1 - Mar 31 · Posted Apr 20, 2026
Expenses
$200,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 6
Copyright/Patent/Trademark

S.1040, to prohibit product hopping and for other purposes; proposals regarding patent thickets

Health Issues

Legislation regarding the Orphan Drug Act and rare disease diagnosis, treatment, and care. Legislation regarding kidney disease and in particular rare kidney disease. HR 1518, the New Era of Preventing End-Stage Kidney Disease Act; end-stage renal disease policy and rare kidney disease

Pharmacy

HR 946 and S. 1862, Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act); related provisions in H.R.1, One Big Beautiful Bill Act; Most Favored Nation and international reference pricing proposals

Medical/Disease Research/Clinical Labs

HR 1262, S 932 Give Kids a Chance Act to renew PRV program; related provisions in H.R.1, One Big Beautiful Bill Act; HR 4709, the Newborn Screening Reauthorization Act; PDUFA/regulatory review process

Medicare/Medicaid

Regulations regarding transparency, reimbursement and care, particularly regarding rare disease. Medicare and Medicaid related provisions in H.R.1, One Big Beautiful Bill Act.

Taxation/Internal Revenue Code

H.R. 1414, Cameron's Law to increase Orphan Drug Tax Credit to 50%; R&D tax credit; related implementation provisions in H.R.1, One Big Beautiful Bill Act; tariffs

 Bills named in this filing 8
  • S. 1040
    A bill to amend title 38, United States Code, to prohibit smoking on the premises of any facility of the Veterans Healt…
  • H.R. 1518
    New Era of Preventing End-Stage Kidney Disease Act
  • H.R. 946
    ORPHAN Cures Act
  • S. 1862
    ORPHAN Cures Act
  • H.R. 1
    One Big Beautiful Bill Act
  • H.R. 1262
    Mikaela Naylon Give Kids a Chance Act
  • H.R. 4709
    Newborn Screening Saves Lives Reauthorization Act of 2025
  • H.R. 1414
    Cameron’s Law

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem